Colorectal Cancer

Recent data reported from the MOUNTAINEER will support a new drug application for tucatinib in patients with metastatic colorectal cancer.

In an interview with Targeted Oncology, Christopher Nevala-Plagemann, MD, discussed the key takeaways of his research on the best treatment strategies for patients with left sided RAS or RAF wild-type metastatic colorectal cancer.

The phase 3 CALGB 9343 study significantly changed prescription patterns for patients with metastatic colorectal cancer, according to a presentation at the International Society for Pharmacoeconomics and Outcomes Research 2022.

Cristian Tomasetti, PhD, discusses the clinical questions that exist among physician who treat patient with stage II colon cancer.

Adding atezolizumab to first-line FOLFOXIRI with bevacizumab is shown to be a safe treatment option and improves progression-free survival in patients with metastatic colorectal cancer.

Enrollment has been completed for the phase 3 PRESERVE 1 trial of trilaciclib in patients with metastatic colorectal cancer receiving chemotherapy.

Research is ongoing to explore all potential uses for circulating tumor DNA to help reduce the global burden of colorectal cancer.

Should the primary tumor, if asymptomatic, be resected in patients with colon cancer with synchronous unresectable metastases? Study results hint that the answer is no.

FOLFOXIRI plus panitumumab should not be recommended as upfront therapy for RAS and BRAF wild-type mCRC patients. according to investigators of the phase 3 TRIPLETE study.

Phase 3 CAIRO5 showed improvements in progression-free survival and overall response with FOLFOXIRI plus bevacizumab in colorectal cancer liver metastases, but the combination demonstrated a toxic safety profile.

Data showing the safety and efficacy of selpercatinib for patients with solid tumors continues to impress clinicians at the 2022 ASCO Annual Meeting.

Improvement in overall survival shown in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab, according to results from the phase 3 PARADIGM trial.

Luv N. Hajirawala, MD, discusses the findings from a retrospective analysis of the Surveillance, Epidemiology and End Results database looking at patients with stage III colon cancer.

The phase 2 MOUNTAINEER trial of tucatinib plus trastazumab in patients with previously treated HER2-positive metastatic colorectal cancer demonstrates positive results.

In an interview with Targeted Oncology, Luv Hajirawala, MD, discussed the relevance of high-risk features in patients with stage III colon cancer, and how a recent real-world analysis may change risk stratification in the future.

Pashtoon M. Kasi, MD, MD, MBBS, MS, discusses the case of a 50-year-old woman with recently diagnosed, unresectable colorectal cancer.

According to new data, different dosing strategies of elimusertib for advanced solid tumors with ATM alterations and other DNA damage repair gene defects has demonstrated early efficacy.

Several notable trials in colorectal cancer suggest a shift in treatment management, especially in the length of treatment with immunotherapies.

In a small safety run-in analysis, no safety concerns were reported with frontline pelareorep in patients with metastatic colorectal cancer.

Charles Meakin, MD, MHA, chief medical officer of Care Oncology, discusses the current colorectal cancer landscape, innovations in detection, and improving patient screening and follow-up care for Colorectal Cancer Awareness Month.

The developer has announced that half of the patients are now enrolled in the BESPOKE CRC clinical trial.

Pending a safety investigation by the developer and further information about risk to patients, the phase 1b trial of CYAD-101 in patients with metastatic colorectal cancer, has been placed on a partial clinical hold by the FDA.

For localized colorectal cancer, the use of circulating tumor tDNA for both quantitative and qualitative detection can inform the risk of recurrence and metastatic dissemination.

During a Targeted Oncology case-based roundtable event, Madappa Kundranda, MD, PhD, and participants discussed the case of a patient with recently diagnosed, unresectable colorectal cancer.

The observational GALAXY study has shown that using a ctDNA assay may help identify which patients with colorectal cancer have the potential to derive benefit from adjuvant chemotherapy.

CheckMate 9X8 trial results indicate a progression-free survival improvement with nivolumab that was not statistically significant.

Promising study results support continued research of T-DXd in patients with HER2-positive mCRC while the risk of potential ILD/pneumonitis requires monitoring.

Afsaneh Barzi, Md, PhD, provides background on a new phase 1/2 studying exploring the combination of regorafenib and pembrolizumab in patients with refractory microsatellite stable colorectal cancer.

In a phase 1/2 study demonstrated that the combination of encorafenib, cetuximab, and nivolumab was well tolerated and led to responses in patients with microsatellite stable BRAFV600E metastatic colorectal cancer.